HOME > About Walvax > Product

Group A and C Meningococcal Polysaccharide Vaccine

 Market Approval time
The product was on market officially in March23, 2012
 Introduction
DESCRIPTION
Group A and C Meningococcal Polysaccharide Vaccine is a preparation of purified capsular polysaccharide antigens extracted from the cultures of Neisseria meningitides group A and C respectively and lyophilized after addition of appropriate lactose as stabilizer. This vaccine is a vaccine in the form of powder and diluent for suspensionfor injection (1 dose of 0.5 mL).
One dose of 0.5ml contains:
Group A Meningococcal Polysaccharide………………………………………..…50μg
Group C Meningococcal Polysaccharide……………………………………..……50μg
Excipients: Lactose andsodium chloride
Diluents: Sterile water for injection

INDICATIONS
The vaccine is used to preventdiseases caused by the bacterium Neisseria Meningitidis group A orC in adults and in children from the age of two years, such as cerebrospinal meningitis and septicemia.
This vaccine does not protect against other groups of meningococci or other organismsresponsible for meningitis or septicaemia (generalized infection).

ADMINISTRATION AND DOSAGE
Reconstitute the vaccine with the accompanying diluent as the stated value. Shake well and inject immediately.
The vaccine should be administeredsubcutaneousin deltoid insertion area of the lateral upper arm.
Each singe human dose is 0.5ml. The immunization shall be carried out before the epidemic season of epidemic cerebrospinal meningitis.

PACKAGING
Vial. 1 dose.

SHELF LIFE
24 months.